22 |
Klinisk Biokemi i Norden · 3 2015
11. Brødbæk K, Gøtze JP. Fatal blødnings-
komplikation hos patient med akut nyres-
vigt behandlet med dabigatran. DSKB Nyt
2013;1:16-8.
12. Schmohl M, Gansser D, Moschetti V, Stangier
J. Measurement of dabigatran plasma con-
centrations by calibrated thrombin clot-
ting time in comparison to LC-MS/MS in
human volunteers on dialysis. Thromb Res
2015;135:532-6.
13. Kubitza D, Perzborn E, Berkowitz SD. The
discovery of rivaroxaban: translating preclini-
cal assessments into clinical practice. Front
Pharmacol 2013;4:145.
14. Rathbun S, Tafur A, Grant R, Esmon N,
Mauer K, Marlar RA. Comparison of methods
to determine rivaroxaban anti-factor Xa acti-
vity. Thromb Res 2015;135:394-397.
15. Cuker A, Siegal DM, Crowther MA, Garcia
DA. Laboratory measurement of the anti-
coagulant activity of the non-vitamin K
oral anticoagulants. J Am Coll Cardiol 2014;
64:1128-39.
16. Bruins Slot KM, Berge E. Factor Xa inhibitors
versus vitamin K antagonists for preventing
cerebral or systemic embolism in patients
with atrial fibrillation. Cochrane Database
Syst Rev 2013;8:CD008980.
17. Dentali F, Riva N, Crowther M, Turpie AG,
Lip GY, Ageno W. Efficacy and safety of the
novel oral anticoagulants in atrial fibrillation:
a systematic review and meta-analysis of the
literature. Circulation 2012; 126:2381-91.
18. Salazar CA, del AD, Cordova EG. Direct
thrombin inhibitors versus vitamin K anta-
gonists for preventing cerebral or systemic
embolism in people with non-valvular atrial
fibrillation. Cochrane Database Syst Rev
2014;3:CD009893.
19. Reilly PA, Lehr T, Haertter S, Connolly SJ,
Yusuf S, Eikelboom JW, et al. The effect of
dabigatran plasma concentrations and patient
characteristics on the frequency of ischemic
stroke and major bleeding in atrial fibrilla-
tion patients: the RE-LY Trial (Randomized
Evaluation of Long-Term Anticoagulation
Therapy). J Am Coll Cardiol 2014;63:321-8.
20. Wallentin L, Yusuf S, Ezekowitz MD, Alings
M, Flather M, Franzosi MG, et al. Efficacy and
safety of dabigatran compared with warfarin
at different levels of international normalised
ratio control for stroke prevention in atrial
fibrillation: an analysis of the RE-LY trial.
Lancet 2010;376:975-83.
21. Dans AL, Connolly SJ, Wallentin L, Yang S,
Nakamya J, Brueckmann M, et al. Concomi-
tant use of antiplatelet therapy with dabiga-
tran or warfarin in the Randomized Evalua-
tion of Long-Term Anticoagulation Therapy
(RE-LY) trial. Circulation 2013; 127:634-40.
Cyklamen (Cyclamen balearicum). Foto: Alexandra Alfthan.
